EGFR and head and neck cancer: Combined EGFR‐targeted therapy and radiotherapy increases the median survival of patients with head and neck malignant tumors from 29.3 months with radiotherapy alone to 49 months without increasing adverse effects such as oral mucositis and dysphagia.2 However, 50% of patients will develop local recurrence.3 Therefore, it is reasonable to deduce that a portion of head and neck squamous cell carcinoma tumors may present radioresistant, even with suppressed EGFR.